Johnson & Johnson’s pharmaceutical arm, Janssen, embarked on a global effort to combat the COVID-19 pandemic. To support their goal of supplying one billion doses of vaccine, an agreement with a contract manufacturer was reached. Large-scale manufacturing of Janssen’s vaccine would take place at the contract manufacturing site, which is designed for rapid manufacturing of vaccines and other treatments in large quantities during public health emergencies.
The beauty of mRNA vaccines is their ability to be quickly updated. Though the vaccine makers are confident in their original vaccines, as COVID-19 continues to change, the vaccines can change, too.
Gaithersburg’s Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for an additional 100 million doses through 2023.
TEDCO recently launched ‘TEDCO Talks’, a series featuring thought leaders in economic development across the State of Maryland. On May 28th, TEDCO CEO & Executive Director, Troy LeMaile-Stovall interviewed Sally Allain, Head of JLABS @ Washington DC, about the future of the innovation ecosystem and the crucial role that JLABS will play in advancing the BioHealth Capital Region.
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced preclinical and clinical data on the company’s original recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, and for a new vaccine directed against the SARS-CoV-2 Beta (B.1.351) variant, which was originally identified in South Africa. The data show that the vaccines demonstrated strong immunogenicity and protection against both the Alpha (B.1.1.7) variant, which was originally identified in the United Kingdom, and the Beta (B.1.351) variant as well as the original SARS-CoV-2 in animal and human studies. A preprint of the manuscript, ‘Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants,’ is available at bioRxiv.org and has been submitted for peer review.